Project 8 - TH17 Dendritic Cell Vaccine
项目8——TH17树突状细胞疫苗
基本信息
- 批准号:9333237
- 负责人:
- 金额:$ 30.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAnimal ModelAntigensBiological Response ModifiersBiostatistics CoreCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCancer EtiologyCancer PatientCancer RemissionCancer VaccinesCell MaturationCell physiologyCellsCessation of lifeCharacteristicsClinicClinicalClinical ResearchClinical TrialsCollaborationsCombined VaccinesCoupledCyclophosphamideCytotoxic T-LymphocytesDataDendritic Cell VaccineDendritic CellsDevelopmentDiseaseDisease remissionEmployee StrikesFOLR1 geneFailureFosteringGenerationsGenetic ModelsGoalsHelper-Inducer T-LymphocyteHumanIL2RA geneImmuneImmune responseImmune systemImmunityImmunosuppressionImmunosuppressive AgentsImmunotherapeutic agentImmunotherapyIndividualInfiltrationInterferon Type IIInterleukin-15Interleukin-17LeadLinkMAP Kinase GeneMAPK14 geneMalignant neoplasm of ovaryMemoryModelingMusMyelogenousMyeloid CellsNo Evidence of DiseaseOutcomeOvarianOvarian StimulationsParalysedPathogenesisPathologicPatient-Focused OutcomesPatientsPeptidesPhasePhase I Clinical TrialsPhenotypePopulationPre-Clinical ModelProteinsRecurrenceRegulatory T-LymphocyteResistanceRoleSafetySignal TransductionStem cellsSuppressor-Effector T-LymphocytesT cell responseT-LymphocyteTestingToxinTumor AntigensVaccinationVaccine DesignVaccinesWorkanergybasecancer immunotherapycell typechemotherapyconventional therapyimmunogenicityimprovedinhibitor/antagonistinnovationinsightmouse modelneoplastic cellnovelnovel strategiesovarian neoplasmoverexpressionpre-clinicalpreclinical efficacypreventprogramsresponsetherapeutic vaccinetraffickingtumortumor growthtumor microenvironmentvaccine developmentvaccine evaluationvaccine trial
项目摘要
PROJECT SUMMARY – Project 8
The host immune response to ovarian cancer (OvCa) has been repeatedly demonstrated and has a dramatic
association with survival; however, for the majority of patients, immune control of OvCa is temporary, and the
tumor cells persist, grow, and ultimately lead to patient death. We and others have shown that this ability of
OvCa to evade host immune responses is due in large part to the influence of regulatory T cells (Tregs) and
suppressive myeloid cells. Both Tregs and suppressive myeloid cells cause anergy of OvCa-reactive T helper
1 (Th1) and CD8 T cells. Tregs are induced not only during endogenous anti-OvCa immune responses, but
also in the context of anti-OvCa immunotherapies, thereby limiting efficacy. Multiple groups have made efforts
to target suppressor cells in OvCa using chemotherapy agents and toxins, but the effects of these agents are
transient and can also deplete beneficial cell types. In contrast, T helper 17 (Th17) cells have been
demonstrated to downregulate these suppressor cells while simultaneously promoting a proinflammatory
antigen-specific immune response. We have recently described a novel strategy of ex vivo DC maturation that
leads to a robust antigen-specific Th17 response. In a model of OvCa, mice treated with Th17-inducing DCs
demonstrated robust anti-OvCa Th17 immune responses, a dramatic reduction in Tregs, and durable OvCa
remissions. In addition to our studies demonstrating the promise of generating Th17 immune responses using
DCs matured ex vivo, we have also identified a novel OvCa antigen, the folate receptor alpha (FRα). This
protein is overexpressed on the vast majority of human (and mouse) OvCa tumors and is linked to worse
clinical outcomes. We have, therefore, identified antigenic peptides from FRα and completed a clinical study
testing these peptides in a therapeutic vaccine. Building on these results, we propose to 1) identify the
immune effectors underpinning the anti-tumor efficacy of Th17-inducing cancer vaccines, 2) determine whether
the induction of Th17 immune responses targeting ovarian cancer antigens will overcome local tumor immune
suppression by inhibiting Treg generation and modulating infiltrating myeloid cell function, and 3) perform a
phase 1 clinical trial to determine whether FRα-specific Th17 T cell responses can be safely generated in
OvCa patients following conventional therapy. Collectively, these aims will help elucidate the mechanisms by
which Th17-inducing DC vaccination suppresses tumor growth, and will provide an assessment of safety and
immunogenicity of this strategy for human OvCa patients, fostering the continuation of a Mayo SPORE
program of innovative immune-based approaches for preventing disease recurrence in OvCa.
项目摘要--项目8
宿主对卵巢癌(OvCa)的免疫反应已被反复证明,并有戏剧性的
然而,对于大多数患者来说,OvCa的免疫控制是暂时的,而
肿瘤细胞持续生长,并最终导致病人死亡。我们和其他人已经证明了这种能力
OvCa逃避宿主免疫反应在很大程度上是由于调节性T细胞(Treg)和
抑制性髓系细胞。树突状细胞和抑制性髓系细胞均可引起卵巢反应性辅助性T细胞无能
1(Th1)和CD8T细胞。Treg不仅在内源性抗OvCa免疫反应中诱导,而且
也在抗OvCa免疫疗法的背景下,从而限制了疗效。多个团体做出了努力
使用化疗药物和毒素来靶向OvCa中的抑制细胞,但这些药物的效果是
暂时性的,也可能耗尽有益的细胞类型。相比之下,T辅助17(Th17)细胞
证明了在下调这些抑制细胞的同时促进促炎
抗原特异性免疫反应。我们最近描述了一种新的体外DC成熟策略
导致强大的抗原特异性Th17反应。在OvCa模型中,Th17诱导的DC治疗小鼠
表现出强大的抗OvCa Th17免疫反应,Tregs显著减少,Ovca持久
减刑。除了我们的研究表明有希望产生Th17免疫反应外,
在DCs体外成熟的基础上,我们还发现了一种新的OvCa抗原--叶酸受体α(FRα)。这
蛋白质在绝大多数人(和小鼠)OvCa肿瘤上过度表达,并与更糟糕的
临床结果。因此,我们已经从FRα中鉴定出抗原肽并完成了一项临床研究
在治疗性疫苗中测试这些多肽。在这些结果的基础上,我们建议1)确定
支持Th17诱导的肿瘤疫苗抗肿瘤效果的免疫效应分子,2)决定了
针对卵巢癌抗原的Th17免疫应答的诱导将克服局部肿瘤免疫
通过抑制Treg的生成和调节浸润性髓系细胞的功能来抑制,以及3)执行
第一阶段临床试验,以确定FRα特异性Th17T细胞反应是否可以安全地在
OvCa患者接受常规治疗。总而言之,这些目标将有助于通过以下方式阐明机制
哪种Th17诱导的DC疫苗可抑制肿瘤生长,并将提供安全性和
这一策略对人卵巢癌患者的免疫原性,促进了梅奥孢子的延续
Ovca预防疾病复发的基于免疫的创新方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Keith L. Knutson其他文献
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia
利用飞行时间质谱流式细胞技术(CyTOF)进行的T细胞免疫聚类分析确定了急性髓系白血病患者的独特亚组
- DOI:
10.1182/bloodadvances.2024014553 - 发表时间:
2025-01-28 - 期刊:
- 影响因子:7.100
- 作者:
Talha Badar;Keith L. Knutson;James Foran;Naseema Gangat;Kevin D. Pavelko;Scott H. Kaufmann;Mark R. Litzow;Hemant Murthy;Davitte Cogen;Margaret Ushman;Arini Arsana;Aref Al-Kali;Hassan Alkhateeb;Ayalew Tefferi;Mrinal Patnaik;Mithun Shah - 通讯作者:
Mithun Shah
RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer
- DOI:
10.1007/s10555-014-9540-2 - 发表时间:
2014-12-30 - 期刊:
- 影响因子:8.700
- 作者:
Keith L. Knutson;Lavakumar Karyampudi;Purushottam Lamichhane;Claudia Preston - 通讯作者:
Claudia Preston
CD4 regulatory T cells in human cancer pathogenesis
- DOI:
10.1007/s00262-006-0194-y - 发表时间:
2006-07-04 - 期刊:
- 影响因子:5.100
- 作者:
Keith L. Knutson;Mary L. Disis;Lupe G. Salazar - 通讯作者:
Lupe G. Salazar
Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”
- DOI:
10.1007/s10549-006-9163-6 - 发表时间:
2006-03-16 - 期刊:
- 影响因子:3.000
- 作者:
Masoud H. Manjili;Hilal Arnouk;Keith L. Knutson;Maciej Kmieciak;Mary L. Disis;John R. Subjeck;A. Latif Kazim - 通讯作者:
A. Latif Kazim
Keith L. Knutson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Keith L. Knutson', 18)}}的其他基金
Analysis of serum folate receptor and antibody level for ovarian cancer detection
卵巢癌检测血清叶酸受体及抗体水平分析
- 批准号:
7288266 - 财政年份:2006
- 资助金额:
$ 30.66万 - 项目类别:
Analysis of serum folate receptor and antibody level for ovarian cancer detection
卵巢癌检测血清叶酸受体及抗体水平分析
- 批准号:
7196223 - 财政年份:2006
- 资助金额:
$ 30.66万 - 项目类别:
HLA classl complex expression in breast cancer immunity
乳腺癌免疫中HLA classl复合物的表达
- 批准号:
7069061 - 财政年份:2005
- 资助金额:
$ 30.66万 - 项目类别:
HLA classl complex expression in breast cancer immunity
乳腺癌免疫中HLA classl复合物的表达
- 批准号:
7587413 - 财政年份:2005
- 资助金额:
$ 30.66万 - 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
- 批准号:
7414086 - 财政年份:2005
- 资助金额:
$ 30.66万 - 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
- 批准号:
7229604 - 财政年份:2005
- 资助金额:
$ 30.66万 - 项目类别:
HLA class l complex expression in breast cancer immunity
乳腺癌免疫中 HLA I 类复合物的表达
- 批准号:
6906817 - 财政年份:2005
- 资助金额:
$ 30.66万 - 项目类别:
Tumor rejection antigens induced via epitope spreading
通过表位扩散诱导肿瘤排斥抗原
- 批准号:
6725807 - 财政年份:2004
- 资助金额:
$ 30.66万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 30.66万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 30.66万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 30.66万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 30.66万 - 项目类别:
Grant-in-Aid for Early-Career Scientists